Skip to content
Innovative Tech
Diseases
Health Policy
HTA
Data Analysis
Clinical Practice
Contributors
BACK TO MAIN SITE
EMA Approval Submission for Teclistamab Multipl...
By
HEOR Staff Writer
March 12, 2026
Johnson & Johnson has submitted a Type II variation application to the
European Cancer Care: Balancing Economic Stability with Improved Survival Rates
FDA Biosimilar Approval Reforms: Accelerating Access and Reducing Drug Costs
FDA Warning Letter Novo Nordisk Reveals Serious Compliance Failures in Advers...
Methodological Gaps in Economic Evaluations of Vaccines: A Systematic Review
Enhertu Early Breast Cancer: FDA Priority Review for Reducing Recurrence Risk
Rapid Genetic Testing Mitigates Gentamicin-Induced Hearing Loss in Neonates
EMA’s Clinical Trials Guidance for Enhancing Flexibility During Public ...
Portugal Clinical Trials Regulation: A Comprehensive Framework for EU Complia...
Aspen Pharmacare Financial Growth: Navigating H1 2026’s Transitional Fi...
South Africa’s Push for Local Lenacapavir Production to Enhance HIV Pre...
Urgent Call for Enhanced Precision Oncology Access in Europe
Harmonizing Non-Clinical Evaluation of Microbiome Medicinal Products in the EU
1
2
3
…
90
Next »